Bausch & Lomb Corp is an eye-health company built around products used to correct, protect, and treat vision across the full patient lifecycle. Its portfolio spans contact lenses, lens care, intraocular lenses, surgical systems, and prescription and consumer eye-care products, giving it exposure to both consumer and clinical channels. The company operates as a fully integrated business with research, manufacturing, and commercial capabilities in roughly 100 countries. It was founded in 1853 and became a separately traded public company in 2022 after being carved out from Bausch Health Companies.
10,5 %
−7,1 %
+6,5 %
1.55
1.04
| % | |
|---|---|
| Vision Care | 57% Contact lenses, lens care, and consumer eye-health products sold through retail and eye-care channels. |
| Pharmaceuticals | 25% Prescription and branded/generic ophthalmic medicines used to treat eye conditions. |
| Surgical | 18% Intraocular lenses, surgical equipment, and related products used in ophthalmic procedures. |
Bausch & Lomb sells to a mix of professional, institutional, and retail customers rather than to a single end market...
Optometrists and ophthalmologists buy or recommend contact lenses, lens care, and consumer eye-health products because they influence patient selection and recurring usage.
These institutions buy IOLs and surgical systems for cataract and other ophthalmic procedures, where product performance and reliability are critical.
They purchase prescription and OTC eye-health products for downstream resale and are important for broad market access.
Large and mid-sized retailers, pharmacies, and mass merchants buy consumer eye-care brands to serve over-the-counter demand.
Consumers buy contact lenses, dry-eye products, vitamins, and supplements for everyday vision correction and eye-health maintenance.
Bausch & Lomb has a global operating footprint with commercial presence in approximately 100 countries, so its revenue...
The company’s strategy centers on being a full-spectrum eye-health platform rather than a single-product business,...
These products drive recurring demand and help the company maintain shelf space and patient loyalty in a competitive market.
Selling multiple eye-health categories through the same customer relationships improves reach and supports cross-selling.
Lower financing risk and a longer-dated debt profile improve flexibility for investment and acquisitions.
Portfolio expansion can fill product gaps and add growth in adjacent eye-health categories.
Bausch & Lomb faces a highly competitive eye-health market where product quality, efficacy, pricing, and promotion...
The company relies on its own plants and third-party manufacturers, so outages or compliance failures can stop shipments and create shortages.
The market includes large pharma, device, OTC, and generic competitors, which can erode pricing and share if rivals launch better or cheaper products.
Higher leverage can raise interest expense, limit strategic flexibility, and make the company more sensitive to credit-market conditions.
Medical devices and pharmaceuticals are subject to quality, safety, and regulatory oversight, and recalls can create charges and reputational damage.
A large share of business is outside the U.S., so currency moves and regional instability can affect reported revenue and margins.
BHC · Pharmaceutical Preparations
JNJ · Pharmaceutical Preparations
Johnson & Johnson is a U.S.-based healthcare company founded in 1887 that develops, manufactures, and sells products for human health and well-being.
COO · Ophthalmic Goods
The Cooper Companies, Inc.
MRK · Pharmaceutical Preparations
SYNSAM.ST · Consumer Discretionary
Synsam Group is a leading optician group in the Nordic region, offering a wide range of products and services for eye health and eye fashion.
PHGE · Biological Products, (No Diagnostic Substances)
: 11/08/2026